Benjamín Rubio-Jurado

Benjamín Rubio-Jurado

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
LALilia Beatriz Aguilar-Lopez
Lilia Beatriz Aguilar-Lopez
JDJosé Luis Delgado-Lamas
José Luis Delgado-Lamas
BRBenjamín Rubio-Jurado
Benjamín Rubio-Jurado
FPFrancisco Javier Perea
Francisco Javier Perea
BIBertha Ibarra
Bertha Ibarra

21 May 2014 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
EMErika Aurora Martínez-García
Erika Aurora Martínez-García
OTOlivia Torres-Bugarín
Olivia Torres-Bugarín
BRBenjamín Rubio-Jurado
Benjamín Rubio-Jurado
CRCarlos Riebeling
Carlos Riebeling
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala

17 December 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
DMDaniela Anahí Méndez-Cobián
Daniela Anahí Méndez-Cobián
SGSandra Guzmán-Silahua
Sandra Guzmán-Silahua
DGDiana García-Hernández
Diana García-Hernández
JCJulian Conde-Sánchez
Julian Conde-Sánchez
YBYaocihuatl Castañeda Borrayo
Yaocihuatl Castañeda Borrayo
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala
Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marrow. Focusing on the Mexican population, this study aims to review GD’s epidemiology, clinical manifestations, and treatment options to enhance early diagnosis and optimize treatment outcomes. Methods: This study is a comprehensive literature review analyzing epidemiological data, clinical presentations, and current therapeutic approaches for Gaucher disease, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Conclusions: Early diagnosis and individualized treatment, primarily through enzyme replacement therapy, significantly improve the prognosis of patients with Gaucher disease, particularly type 1. Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease’s epidemiology in Mexico. These efforts will contribute to improved clinical outcomes and quality of life for patients.

24 July 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Daniel Sat-MuñozDaniel Sat-Muñoz
Daniel Sat-Muñoz
BHBrenda Eugenia Martinez Herrera
Brenda Eugenia Martinez Herrera
JGJavier-Andrés González-Rodríguez
Javier-Andrés González-Rodríguez
LGLeonardo-Xicotencatl Gutiérrez-Rodríguez
Leonardo-Xicotencatl Gutiérrez-Rodríguez
BENJAMIN TRUJILLO-HERNANDEZBENJAMIN TRUJILLO-HERNANDEZ
BENJAMIN TRUJILLO-HERNANDEZ
Luz-Ma-Adriana Balderas-PenaLuz-Ma-Adriana Balderas-Pena
Luz-Ma-Adriana Balderas-Pena
In patients with head and neck cancer, malnutrition is common. Most cases are treated by chemo-radiotherapy and surgery, with adverse effects on the aerodigestive area. Clinical and biochemical characteristics, health-related quality of life, survival, and risk of death were studied. The selected subjects were divided into normal- and low-phase-angle (PA) groups and followed up for at least two years. Mean ages were 67.2 and 59.3 years for low and normal PA, respectively. Patients with PA < 4.42° had significant differences in age, anthropometric and biochemical indicators of malnutrition, and inflammatory status compared to patients with PA > 4.42°. Statistical differences were found in the functional and symptom scales, with lower functional scores and higher symptom scores in patients with low PA. Median survival was 19.8 months for those with PA < 4.42° versus 34.4 months for those with PA > 4.42° (p < 0.001).The relative risk of death was related to low PA (2.6; p < 0.001). The percentage of living patients (41.7%) is almost the same as the percentage of deceased subjects (43.1%; p = 0.002), with high death rates in patients with PA < 4.42°. Phase angle was the most crucial predictor of survival and a risk factor for death in the studied cases.

1 January 2018
Verified
Book Chapter
Closed access
BRBenjamín Rubio-Jurado
Benjamín Rubio-Jurado
Luz-Ma-Adriana Balderas-PenaLuz-Ma-Adriana Balderas-Pena
Luz-Ma-Adriana Balderas-Pena
EGEduardo E. García-Luna
Eduardo E. García-Luna
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
CRCarlos Riebeling-Navarro
Carlos Riebeling-Navarro
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala

Verified
Journal Article
Open access
PDF file
SBSonia Guadalupe Barreno-Rocha
Sonia Guadalupe Barreno-Rocha
SGSandra Guzmán-Silahua
Sandra Guzmán-Silahua
SRSinaí-Del-Carmen Rodríguez-Dávila
Sinaí-Del-Carmen Rodríguez-Dávila
GGGuadalupe Estela Gavilánez-Chávez
Guadalupe Estela Gavilánez-Chávez
EMErnesto Germán Cardona Muñoz
Ernesto Germán Cardona Muñoz
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala
One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-β2 glycoprotein I (anti-β2GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.